Key facts
- It has raised $4.4M across 1 recorded rounds; the latest was Seed Round ($1.7M) in Oct 2019.
- Notable investors include Gaingels, Ben Franklin Technology Partners of Northeastern Pennsylvania, Robin Hood Ventures, Viva BioInnovator, Delaware Crossing Investor Group — 9 tracked in total.
- Ophidion has filed 2 Form Ds with the SEC since 2019, most recently Jan 2020 ($1.7M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Ophidion
Funding rounds
1 roundsAbout Ophidion
Developer of gene-silencing therapies designed to treat neurodegenerative diseases following intravenous administration. The company's platform uses a trojan horse strategy to exploit an endogenous receptor-mediated transport system to deliver oligonucleotides and small interfering ribonucleic acids (siRNAs) following intravenous administration into the brain, enabling physicians to deliver therapeutics for the treatment of various central nervous system (CNS) disorders and brain malignancies.
- Sector
- Healthcare
- HQ
- Pasadena, CA, United States
- Founded
- 2008
- Employees
- 8
- Website
- ophidion.com/
- Ownership
- Privately Held (backing)
Ophidion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ophidion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ophidion in its N-PORT filings yet. We sweep new filings monthly.